Logotype for OnKure Therapeutics Inc

OnKure Therapeutics (OKUR) investor relations material

OnKure Therapeutics Q2 2025 earnings summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for OnKure Therapeutics Inc
Q2 2025 earnings summary12 Aug, 2025

Executive summary

  • Completed merger with Reneo Pharmaceuticals, resulting in a reverse recapitalization and $65M concurrent financing; now trades on Nasdaq as OKUR.

  • Focused on advancing lead candidate OKI-219, a selective PI3Kα inhibitor, in Phase 1a/1b clinical trials for advanced breast cancer.

  • Completed enrollment in single agent and fulvestrant combination arms of PIKture-01 trial for OKI-219; data expected Q4 2025.

  • Initiated new expansion arms to evaluate OKI-219 in triplet combinations for HR+ and HER2+ metastatic breast cancer.

  • No product revenue to date; operations funded primarily through equity and convertible debt.

Financial highlights

  • Cash and cash equivalents totaled $83.4M as of June 30, 2025, providing runway into Q4 2026.

  • R&D expenses were $12.6M for Q2 2025, up from $10.8M in Q2 2024, mainly due to increased clinical and manufacturing costs.

  • G&A expenses were $3.7M for Q2 2025, slightly higher than $3.6M in Q2 2024, driven by personnel and professional fees.

  • Net loss for Q2 2025 was $15.4M ($1.14 per share), compared to $14.1M in Q2 2024.

  • Cash used in operating activities was $27.3M for the six months ended June 30, 2025.

Outlook and guidance

  • Expects R&D and G&A expenses to increase in 2025 as clinical programs advance and public company operations continue.

  • Data from PIKture-01 monotherapy and fulvestrant combination arms expected in Q4 2025.

  • Nomination of a pan-mutant selective PI3Ka inhibitor development candidate planned by end of 2025.

  • Cash runway projected into Q4 2026 based on current cash position.

  • Additional capital will be required to complete product development and commercialization; may seek equity, debt, or partnership funding.

Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Your earnings 
season toolkit.
Download
Free on both iOS & Android.

The essential earnings season companion

The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

Live calls and transcripts

Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.

Find what you need faster

Search for any keyword across all transcripts simultaneously.

Easily store key findings

Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Your watchlist. Your dashboard.

Follow the companies that matter to you. Get a personalized feed with real-time updates.

Be the first to know

Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.

Consensus estimates

Access analyst consensus estimates, valuation multiples, and revenue segments splits.

All IR material in one place

The easiest way to stay updated during earnings season.

Global coverage

All events from public companies. Live and recorded.

Just click and listen

No webcast links. No manual registrations.

Research anytime, anywhere

Built for professionals. Loved by everyone. Try our free mobile app.

excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com

Frequently asked questions

Reneo Pharmaceuticals Inc. is a clinical-stage pharmaceutical company focused on developing therapies for patients with rare genetic mitochondrial diseases. These diseases often involve the mitochondria's inability to efficiently produce energy for cells, impacting various bodily functions. The company is headquartered in San Diego, California, and its shares are listed on the Nasdaq.

Quartr provides global coverage of all investor relation material from public companies.

  • Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

  • Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.

  • Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.

Yes, the Quartr mobile app is free on both iOS and Android.

Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.

Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.

Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.

Explore our global coverage